BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-07-18 22:00 |
BioArctic: Late breaking Phase 2b study results of BAN2401 in Alzheimer’s disea…
|
English | 255.9 KB | ||
| 2018-07-18 22:00 |
BioArctic: Senaste resultat från BAN2401 Fas 2b-studien i Alzheimer patienter k…
|
Swedish | 228.7 KB | ||
| 2018-07-10 12:30 |
BioArctic receives regulatory approval in Finland for a clinical study in patie…
|
English | 188.1 KB | ||
| 2018-07-10 12:30 |
BioArctic får myndighetsgodkännande i Finland för klinisk studie med patienter …
|
Swedish | 187.6 KB | ||
| 2018-07-06 01:30 |
BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months i…
|
English | 227.0 KB | ||
| 2018-07-06 01:30 |
BioArctic meddelar positiva 18 månaders resultat i Fas 2b-studien med BAN2401 i…
|
Swedish | 225.7 KB | ||
| 2018-06-27 07:00 |
BioArctic announces changes in the Management Team effective September 1, 2018
|
English | 176.4 KB | ||
| 2018-06-27 07:00 |
BioArctic meddelar förändringar i ledningsgruppen per den 1 september 2018
|
Swedish | 179.5 KB | ||
| 2018-05-15 20:00 |
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I BIOARCTIC (PUBL)
|
Swedish | 170.5 KB | ||
| 2018-05-15 20:00 |
REPORT FROM THE ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)
|
English | 179.8 KB | ||
| 2018-05-14 10:30 |
BioArctic utvidgar forskningssamarbetet med Uppsala universitet kring ny antikr…
|
Swedish | 178.1 KB | ||
| 2018-05-14 10:30 |
BioArctic extends the research collaboration with Uppsala University regarding …
|
English | 177.0 KB | ||
| 2018-04-26 08:00 | Swedish | 471.4 KB | |||
| 2018-04-26 08:00 | English | 505.4 KB | |||
| 2018-04-25 11:00 |
Inklusionen av patienter med komplett ryggmärgsskada till den första panelen av…
|
Swedish | 186.6 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
